Catalysts for Moberg Pharma AB
18 tracked
Dec 22, 2025
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Dec 22, 2025
approval
FLOWTUSS (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Dec 22, 2025
approval
HYCOFENIX (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Nov 27, 2024
recall
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)
Moberg Pharma AB
→
Nov 27, 2024
recall
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)
Moberg Pharma AB
→
Dec 15, 2023
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Dec 15, 2023
approval
FLOWTUSS (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Dec 15, 2023
approval
HYCOFENIX (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jun 28, 2018
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jun 28, 2018
approval
FLOWTUSS (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jun 28, 2018
approval
HYCOFENIX (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jan 13, 2017
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jan 13, 2017
approval
FLOWTUSS (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jan 13, 2017
approval
HYCOFENIX (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Jun 19, 2015
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
May 14, 2015
approval
FLOWTUSS (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
May 14, 2015
approval
HYCOFENIX (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→
Nov 14, 2014
approval
OBREDON (GUAIFENESIN) — FDA approval
Moberg Pharma AB
→